Disc Medicine (IRON) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Disc Medicine (IRON) over the past year, gaining 116.5% versus a loss of 13.5%. Over five years, IRON leads with a -45.5% price change compared with -80.6% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.76 billion vs $2.38 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | MRVI |
|---|---|---|
| Share price | $62.06 | $7.44 |
| Market cap | $2.38B | $2.76B |
| 1-day change | +2.12% | +3.19% |
| YTD return | -23.47% | +121.85% |
| 1-year return | -13.53% | +116.52% |
| 5-year return | -45.55% | -80.56% |
| EPS (TTM) | $-6.58 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-212.18M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $99.50 | $9.42 |
| 52-week low | $40.00 | $2.55 |
| Distance from 52-week high | -37.63% | -21.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +66.24% | +5.24% |
| Average volume | 471.18K | 3.36M |
| Shares outstanding | 38.39M | 148.99M |
| Employees | 165 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed IRON by 130.0 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
IRON vs MRVI FAQ
Which is bigger, Disc Medicine or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.76B compared with $2.38B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or MRVI?
MRVI returned +116.52% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.